Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIT-GC: Neoadjuvant Iparomlimab + Tuvonralimab in Resectable MSI-H/dMMR Gastric/GEJ Cancer
ChiCTR2500111960Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab and tuvonralimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Pathological Complete Response, Clinical Complete Response at 8–12 Weeks and 1 more. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500111960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111960.